AI Terminal
HEMOGENYX PHARMACEUTICALS PLC
Director's Dealing • May 30, 2022
4938_dirs_2022-05-30_d3137f7e-fc7d-4372-9dcc-19f76fb96951.html
Director's Dealing
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 1653N
Hemogenyx Pharmaceuticals PLC
30 May 2022
30 May 2022
Hemogenyx Pharmaceuticals plc
("Hemogenyx Pharmaceuticals" or the "Company")
LEI 2138008L93GYU5GN6179
Director/PDMR Shareholding
Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it has been notified that Andrew Wright, the Company's Financial Controller and Company Secretary (PDMR), has purchased 1,284,889 ordinary shares of £0.01 each in the Company ("Ordinary Shares") at a price of 1.44p per share. Following this transaction, Mr Wright has a total beneficial interest in 4,000,000 Ordinary Shares, representing approximately 0.41 per cent of the Company's issued share capital.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:
1.
Details of PDMR/person closely associated with them ("PCA")
a)
Name
Andrew Wright
2.
Reason for the notification
a)
Position/status
Financial Controller and Company Secretary
b)
Initial notification/
amendment
Initial notification
3.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Full name of the entity
Hemogenyx Pharmaceuticals plc
b)
Legal Entity Identifier code
2138008L93GYU5GN6179
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Ordinary shares of Hemogenyx Pharmaceuticals plc
GB00BYX3WZ24
b)
Nature of the transaction
Standalone acquisition of shares
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| GBP £0.0144 | 1,284,889 |
d)
Aggregated information
- Aggregated volume
- Price
| Price(s) | Volume(s) |
| GBP £18,502.40 | 1,284,889 |
e)
Date of the transaction
2022-05-27
f)
Place of the transaction
London Stock Exchange
XLON
Enquiries:
| Hemogenyx Pharmaceuticals plc | https://hemogenyx.com |
| Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | [email protected] |
| Peter Redmond, Director | [email protected] |
| SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
| Matthew Johnson, Vadim Alexandre, Adam Cowl | |
| Peterhouse Capital Limited | Tel: +44 (0)20 7469 0930 |
| Lucy Williams, Duncan Vasey, Charles Goodfellow | |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHDBGDULBDDGDC